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Abstract
Naphthalimides, particularly amonafide and 2-(2-dimethylamino)-6-thia-2-aza-benzo[def ]chrysene-1,3-diones (R16),
have been identified to possess anticancer activities and to induce G2-M arrest through inhibiting topoisomerase II
accompanied by Chk1 degradation. The current study was designed to precisely dissect the signaling pathway(s)
responsible for the naphthalimide-induced cell cycle arrest in human colon carcinomaHCT116 cells. Using phosphory-
lated histone H3 and mitotic protein monoclonal 2 as mitosis markers, we first specified the G2 arrest elicited by the
R16 and amonafide. Then, R16 and amonafide were revealed to induce phosphorylation of the DNA damage sensor
ataxia telangiectasia–mutated (ATM) responding to DNA double-strand breaks (DSBs). Inhibition of ATM by both the
pharmacological inhibitor caffeine and the specific small interference RNA (siRNA) rescued the G2 arrest elicited by
R16, indicating its ATM-dependent characteristic. Furthermore, depletion of Chk2, but not Chk1 with their corre-
sponding siRNA, statistically significantly reversed the R16- and amonafide-triggered G2 arrest. Moreover, the naphtha-
limides phosphorylated Chk2 in an ATM-dependent manner but induced Chk1 degradation. These data indicate that
R16 and amonafide preferentially used Chk2 as evidenced by the differential ATM-executed phosphorylation of Chk1
and Chk2. Thus, a clear signaling pathway can be established, in which ATM relays the DNA DSBs signaling triggered
by the naphthalimides to the checkpoint kinases, predominantly to Chk2, which finally elicits G2 arrest. Themechanistic
elucidation not only favors the development of the naphthalimides as anticancer agents but also provides an alternative
strategy of Chk2 inhibition to potentiate the anticancer activities of these agents.
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Introduction
Naphthalimides are important anticancer compounds that bind to
DNA by intercalation, showing potent anticancer activity against
human cancers preclinically and clinically [1–6]. However, early
naphthalimides, for example, amonafide (Figure 1), although effective
in its phase 2 clinical trials when administered either alone or in com-
bination, suffered from the dose-limiting bone marrow toxicity caused
by the toxic N -acetyl-amonafide generated through N -acetylation by
N -acetyltransferase 2 (NAT2). Especially unacceptably, this hemato-
toxicity was highly variable and unpredictable owing to NAT2, the
polymorphic enzyme with differential activity between individuals
[1,4–6]. To get rid of such unpredictable thus unacceptable toxicity, per-
sistent efforts have been put into eliminating the site on naphthalimides
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catalyzed by NAT2, which resulted in the emergence of a new gen-
eration of naphthalimide analogs, represented by UNBS5162 [2,3]
and 2-(2-dimethylamino)-6-thia-2-aza-benzo[def ]chrysene-1,3-diones
(R16; Figure 1) [7]. These new-generation naphthalimide analogs not
only remove the potential unpredictable toxicity risks of the early ones
but also retain their anticancer activity. Moreover, some of them such
as UNBS5162 are conferred to distinct mechanisms of action [3]. Cur-
rently, UNBS5162 is undergoing phase 1 clinical trials in cancer patients
with advanced solid tumors or lymphoma [2,3], which makes it reason-
able to expect that this class of compounds enter clinical anticancer use.
Although UNBS5162 uniquely antagonizes CXCL chemokine ex-
pression [3], the naphthalimides amonafide and R16 inhibit DNA
topoisomerase II (Top2) and trap Top2 cleavable complexes [7]. Also,
like other Top2 inhibitors, both amonafide and R16 induce DNA
double-strand breaks (DSBs) and arrest cells at the G2-M phase [7];
however, unlike etoposide (VP16) and adriamycin (ADR), they exhibit
significant anti–multidrug resistance abilities [7]. In addition, we have
shown that R16 induces degradation of Chk1 through the ubiquitin-
proteasome pathway and impairs the function of this kinase [8]. We are
therefore inspired to further dissect molecular signaling pathway(s) that
are used in inducing cell cycle arrest, so as to have a clear understand-
ing of naphthalimides as promising anticancer candidates and to find
out manipulable strategies to achieve better efficiency in their potential
clinical uses.
Cell cycle checkpoints ensure the orderly and timely progression of
some critical events such as DNA replication and chromosome seg-
regation in cells. More importantly, cell cycle arrest may play a criti-
cal role in mediating the chemotherapeutic effects of Top2 inhibitors
[9]. In response to DNA DSBs, checkpoint signaling pathways are
activated to arrest cells at G1/S, S, or G2/M transitions, thus allow-
ing time to repair the damage or, in the case of unrepairable lesions, to
execute apoptosis. Ataxia telangiectasia–mutated (ATM) and ATM-
Rad3–related (ATR) have been well documented as two apical protein
kinases in DNA damage response pathways [10]. Generally, ATM pri-
marily responds to ionizing radiation-induced DNA DSBs, whereas
ATR is activated by stalled replication resulting from UV and some
genotoxic drugs [11]. Two structurally unrelated but functionally simi-
lar protein serine/threonine kinases Chk1 and Chk2 are the substrates
of ATM and ATR. Chk2 is phosphorylated by ATM at Thr68 and
thus activated [12], whereas Chk1 activation requires phosphorylation
at Ser317 and Ser345 catalyzed by ATM and/or ATR [13,14]. The
activated checkpoint kinases phosphorylate their substrates such as
Cdc25C that regulate the activity of the Cdc2–cylcin B1 complex, a
cyclin-dependent kinase complex functioning as an ultimate target of
the G2 checkpoint signaling pathway [15].
The present study used amonafide and R16 to define the underlying
mechanism by which the naphthalimides induce cell cycle arrest of tu-
mor cells. We first used phosphorylated histone H3 antibody and the
mitosis-specific monoclonal antibody mitotic protein monoclonal 2
(MPM-2) as mitosis markers to define that the naphthalimides arrested
HCT116 cells at the G2 phase but not at the M phase. Then using
pharmacological inhibitors and the small interference RNA (siRNA)
technology, we dissected for the first time how amonafide and R16 ac-
tivated the ATM-Chk2 pathway to arrest cells at the G2 phase. The
current findings greatly extend our previous study by elucidating the
detailed molecular mechanism of amonafide- and R16-driven cell cycle
arrest, which will possibly benefit the clinical trials of the naphtha-
limides for cancer therapy.
Materials and Methods
Reagents
R16 was synthesized, and its purity was more than 99% [7]. The
parental compound amonafide was obtained from the Drug Synthesis
and Chemistry Branch, Division of Cancer Treatment, National Can-
cer Institute (Bethesda, MD). VP16, ADR, camptothecin, hydroxyurea
(HU), and caffeine were purchased from Sigma (St Louise, MO). All
these compounds except caffeine were dissolved in dimethyl sulfoxide
as stock solutions of 10 mM (R16, amonafide, and camptothecin) or
20mM (VP16 and ADR). Caffeine (80 mM) was dissolved in sterilized
water. The stock solutions were kept frozen in aliquot at −20°C and
thawed immediately before each experiment.
Cell Culture
Human colorectal carcinoma HCT116 cells were obtained from
the American Type Culture Collection (Manassas, VA) and maintained
in McCoy 5A medium (Life Technologies, Grand Island, NE) sup-
plemented with 10% heat-inactivated fetal calf serum (Life Technolo-
gies), L-glutamine (2 mM), penicillin (100 IU/ml), streptomycin
(100 μg/ml), and HEPES (10 mM, pH 7.4) at 37°C and 5% CO2
in a humid environment.
Flow Cytometry
The distribution of HCT116 cells at different stages in the cell cycle
was estimated by flow cytometric DNA analyses. Briefly, 5 × 105 cells
were incubated overnight in six-well plates in McCoy 5A medium con-
taining 10% FBS, then treated with or without various concentrations
of compounds for indicated times, in untransfected cells or in trans-
fected cells. Cells were harvested and washed with phosphate-buffered
saline (PBS; pH 7.4), fixed with 70% ethanol/30% PBS at 4°C. Fol-
lowed by PBS washing, the pellet was dissolved in RNaseA solu-
tion (20 μg/ml) and incubated at 37°C for 15 minutes, stained with
propidium iodide (Sigma) for 30 minutes in the dark at room tem-
perature. For each sample at least 1 × 104 cells were analyzed using a
FACS-Calibur cytometer (Becton Dickinson, San Jose, CA), and the
percentage of cells in each cell cycle phase was calculated using the
CELLQUEST and ModFITLT software packages (Becton Dickinson).
Neutral Single-Cell Gel Electrophoresis Assays
DNA DSBs were evaluated using neutral single-cell gel electro-
phoresis (NSCGE) assays as previously described [16,17]. Briefly, after
Figure 1. Chemical structures of amonafide and R16.
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treatments with the indicated agents, cells were harvested, mixed with
low–melting point agarose, layered onto microscope slides precoated
with normal–melting point agarose, then solidified, lysed, equilibrated,
electrophoresed, and then stained with 4′,6-diamidino-2-phenylindole.
Cells were viewed using an Olympus BX51 fluorescence microscope
(Olympus, Tokyo, Japan).
Western Blot Analysis
Standard Western blot analyses were done by using the following ap-
propriate primary antibodies to phospho-Chk1 (Ser345), γ-H2AX, phos-
phorylated histone H3, and histone H3 (Cell Signaling Technology,
Beverly, MA); Chk1 and cyclin B1 (Santa Cruz Biotech, Santa Cruz,
CA); phospho-Chk2 (Thr68; R&D systems, Inc, Minneapolis, MN);
phospho-ATM (Ser1981) and ATM (Rockland Immunochemicals,
Gilbertsville, PA); ATR (Calbiochem,La Jolla,CA); andMPM-2 (Upstate,
Lake Placid, NY). Proteins were visualized with peroxidase-coupled sec-
ondary antibodies (Calbiochem; diluted 1:2000), using ECL-plus kit from
Amersham Biosciences (Buckinghamshire, UK) for detection.
siRNA Transfection
All the siRNA sequences were duplexes of 21-mer RNA with a
2-mer 3′ overhang produced by Genepharma, Co (Shanghai, China).
The ATM targeting sequences are 5′-AACATACTACTCAAAGA-
CATT-3′ [18] for ATM siRNA1 and 5′-AAGCAC CAGUCCA-
GUAUUGGC-3′ [19] for ATM siRNA2, the ATR targeting sequence
is 5′-AACCTCCGTGATGTTGCTTGA-3′ [20], the Chk1 targeting
sequence is 5′-AAGTTCAACTTGCTGTGAATA-3′ [21], and the
Chk2 targeting sequence is 5′-AAGAACCUGAGGACCAAGAAC-3′
[22]. Cells (2 × 105) were incubated overnight in six-well dishes in
McCoy 5A medium containing 10% FBS. The medium was replaced
with fresh Opti-MEM (Life Technologies) containing siRNA and
Oligofectamine (Invitrogen, Carlsbad, CA) according to the manufac-
turer’s recommendations. After 4 hours, Opti-MEM was changed to
McCoy 5A medium containing 10% bovine serum, and incubation
was continued for another 24 hours. After exposure to different com-
pounds for indicated times, treated or untreated cells were collected for
Western blot analyses for protein expression and for flow cytometry.
Figure 2. R16 arrests HCT116 cells at G2 phase. (A and B) R16 and amonafide increased the G2/M population of HCT116 cells in a
concentration-dependent manner. HCT116 cells were treated with different compounds at indicated concentrations for 24 hours and then
subjected to flow cytometry. The data were expressed as mean ± SD from three independent experiments (A) and the typical histograms
were shown (B). (C) R16 and amonafide increased the G2/M population in a time-dependent fashion. HCT116 cells were treated with R16
(2.5 μM) or amonafide (2.5 μM) for the different periods and were then subjected to flow cytometry. The data were expressed as mean ±
SD from three independent experiments. (D and E) Treatments with R16 or amonafide did not increase the molecular markers of mitosis
arrest phosphorylated histone H3 (p-Histone H3) and MPM-2. HCT116 cells were treated with indicated concentrations of the tested com-
pounds for 24 hours and were then subjected to Western blot analysis. All the Top2 inhibitors (R16, amonafide, VP16, and ADR) did not
increase p-Histone H3 (D) and MPM-2 (E) as the mitosis inhibitor vincristine did (D and E). The images were representative of three sepa-
rate experiments.
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Immunofluorescence Analyses
For immunofluorescence analyses, treated or untreated cells growing
on coverslips were rinsed with PBS, fixed with 4% paraformaldehyde
for 15 minutes and permeabilized with 0.1% Triton X-100 in PBS
for 10 minutes. The samples were blocked with TBS/3% BSA for
30 minutes, incubated with the p-ATM (Ser1981) antibody (Rockland
Immunochemicals; diluted 1:100) for 60minutes at room temperature.
After three washes with TBS, samples were incubated with fluores-
cent secondary Alexa Fluor 488 anti–rabbit serum immunoglobulin G
(diluted 1:200; Molecular Probes, Eugene, OR) 60 minutes, then
washed with TBS and incubated with 4′,6-diamidino-2-phenylindole
for 5 minutes. Images were photographed using a Leica TCSSP2 con-
focal microscope (Leica, Mannheim, German) or an Olympus BX51
fluorescence microscope (Olympus). Quantitation was performed by
analyzing at least 100 randomly selected cells per slide.
Results
Naphthalimides Arrest Cell Cycle at the G2 Phase
We have demonstrated that both amonafide and R16 trigger signifi-
cant G2-M arrest in human promyelocytic leukemia HL-60 cells [7].
We have also found that R16 induces the degradation of Chk1 protein
in various solid tumor cells including human colon cancer HCT116,
rhabdomyosarcoma Rh30, lung cancer A549, and cervical cancer HeLa
cells and revealed the involvement of the ubiquitin-proteasome path-
way in this action of R16 in HCT116 cells [8]. We thus ask how and
Figure 3. DNA DSBs contribute to R16-mediated G2 arrest. (A and B) R16 and amonafide induced DNA DSBs. HCT116 cells were treated
with different compounds at indicated concentrations for 2 hours and were then subjected to Western blot analysis to detect the level of
γ-H2Ax (A) or to NSCGE assays to detect the broken DNA (comet tails; B). (C) R16 (10 μM for 2 hours) induced the formation of p-ATM
foci in HCT116 cells detected by immunofluorescence assays. (D) R16 and amonafide (at indicated concentrations for 2 hours) in-
creased the phosphorylation of ATM detected by Western blot analysis. (E and F) The ATM/ATR inhibitor caffeine (2 mM, 30 minutes)
abrogated R16- and amonafide-induced (24 hours) G2 arrest in HCT116 cells detected by flow cytometry. The data were expressed as
the typical histograms (E) or as mean ± SD from three independent experiments (F), *P < .05; **P < .01.
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why these naphthalimides impact on the cell cycle progression in solid
tumor cells. To answer the questions, we used HCT116 cells because
the cells have been successfully used to investigate the effect of R16
on Chk1 protein, one of the most important cell cycle checkpoint
kinases. Treatments with amonafide or R16 led to prominent G2-M
arrest in concentration- and time-dependent manners in HCT116
cells (Figure 2, A–C ). To precisely define whether the G2-M arrest is
G2 or M phase arrest, we used two well-characterized mitosis markers
phosphorylated histone H3 [23] and MPM-2 (a monoclonal antibody
interacting with mitosis-specific phosphorylated proteins [24]). As
expected, the mitosis inhibitor vincristine dramatically upregulated phos-
phorylated histone H3 and MPM-2, both of which, however, were un-
detectable in the cells exposed to all the Top2 inhibitors R16, amonafide,
VP16, and ADR at the conditions of effectively arresting cell cycle pro-
gression (Figure 2, D and E ). The data indicate that the naphthalimides
R16 and amonafide arrest cell cycle at the G2 phase not at the M phase
in HCT116 cells. Moreover, this result was further confirmed by using
human colon cancer HT29 and cervical cancer HeLa cells.
DNA DSBs Contribute to G2 Arrest Caused by R16
The ability of amonafide and R16 to induce DNA DSBs by inhib-
iting Top2 has been shown in HL-60 cells [7]. To investigate the
mechanism of G2 arrest elicited by naphthalimides, we first validated
this ability of amonafide and R16 by detecting the levels of the phos-
phorylated histone γ-H2AX. HCT116 cells treated with 20 μM R16
or 20 μM amonafide for 2 hours exhibited comparable increased
Figure 4. Depletion of ATM but not ATR abates the G2 arrest elicited by R16 and amonafide. (A and B) ATM knockdown rescued HCT116
cells from the G2 arrest triggered by R16 and amonafide. Cells were transfected with 100 nM ATM siRNA1 (A) or 100 nM ATM siRNA2
(B) for 24 hours before being exposed to R16 or amonafide for the following 24 hours. Then the cell cycle distribution was analyzed by
flow cytometry. Left panel indicates the efficiency of ATM depletion; middle panel, typical histograms; right panel, mean ± SD from
three separate experiments. *P < .05; **P < .01. (C) ATR knockdown with ATR siRNA (100 nM) did not prevent the G2 arrest induced by
R16 and amonafide although it effectively abated the S arrest elicited by HU. HCT116 cells were transfected with 100 nM ATR siRNA for
24 hours before the treatment with different compounds at the indicated concentrations for the following 24 hours. Left panel indicates
the efficiency of ATR depletion; middle panel, S arrest and HU; right panel, G2/M arrest and R16, amonafide, VP16, and ADR. The data
were expressed as mean ± SD from three independent experiments; *P < .05.
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phosphorylation levels of γ-H2AX with those of the cells exposed to
the references VP16 or ADR (Figure 3A). This result was further di-
rectly confirmed by using the NSCGE (comet assays), a widely used
method for measuring cellular DNA DSBs. The exposure to R16 or
amonafide for 2 hours produced typical comet tails in HCT116 cells,
an evident indicator of DNA DSBs (Figure 3B). Moreover, both
amonafide and R16 induced the formation of p-ATM (Ser1981) foci
in the treated cells (Figure 3C ) and the enhanced levels of phosphory-
lated ATM (Ser1981; Figure 3D), indicating that the DNA DSBs
activated the ATM signaling pathway. More importantly, caffeine, a
well-known ATM/ATR inhibitor, effectively prevented the G2 arrest
induced by amonafide or R16 (Figure 3, E and F ). The data collec-
tively indicate that amonafide and R16 trigger DNA DSBs that con-
tribute to the G2 arrest in HCT116 cells.
ATM Is Indispensable for R16-Driven G2 Arrest
Both ATM and ATR have been reported to activate cell cycle check-
points and relay signals to the downstream kinases including Chk1 and
Chk2. To examine whether the G2 arrest induced by naphthalimides
is dependent of ATM and ATR, we knocked down ATM and ATR
with their respective specific siRNA. ATM-targeting siRNA1 down-
regulated the protein expression of ATM in transfected HCT116 cells,
and at the same time, apparently abated R16-induced G2 arrest, as
indicated by the fact that ATM siRNA1 decreased G2 population from
49.02% to 33.56% in response to the treatment with R16 (Figure 4A).
In amonafide-treated cells, similar abrogation was observed (Figure 4A).
At the same time, neither the level of ATM nor the cell cycle distribution
was affected in mock siRNA-transfected cells. In addition, another ATM
siRNA, ATM siRNA2, was used to further confirm the indispensability
Figure 5. Depletion of Chk2 but not Chk1 prevents the G2 arrest induced by R16 and amonafide. (A) Chk1 knockdown with its siRNA
(100 nM) did not decrease the G2 arrest triggered by R16 and amonafide statistically significantly although reducing the G2 arrest trig-
gered by the other two Top2 inhibitors VP16 and ADR. Left panel indicates the efficiency of Chk1 depletion; right panel, mean ± SD
from three separate experiments. *P < .05. (B and C) Silencing of Chk2 diminished G2 arrest but potentiated apoptosis induction by R16
significantly. HCT116 ells were treated with the compounds at the indicated concentrations for 24 hours after Chk2 silencing with its
siRNA (100 nM, 24 hours). Then the cells were subjected to flow cytometry. The percentage of G2 population (B) or apoptotic cells (C)
were expressed as mean ± SD from three separate experiments. *P< .05. B: Left panel indicates the efficiency of Chk2 depletion; right
panel, mean ± SD of G2 population (%). *P < .05. C: Left panel indicates typical histograms to show the sub-G1 population (apoptotic
cells); right panel, mean ± SD of apoptotic cells (%). *P < .05.
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of ATM in R16-induced G2 arrest. Silencing ATM with ATM siRNA2
(100 nM) effectively attenuated the G2 population in R16 (2.5 μM,
24 hours)-treated cells, from 65.44% to 42.87% (Figure 4B).
Furthermore, the role of ATR, a kinase related to ATM, in R16-
or amonafide-caused G2 arrest was investigated. Silencing ATR with
ATR-specific siRNA decreased the level of ATR protein in HCT116
cells but imposed minimal effects on the cell cycle distribution in R16-
and amonafide-treated cells (Figure 4C ). In contrast, transfection with the
same ATR siRNA attenuated the S arrest induced by HU (0.5 mM,
24 hours) in HCT116 cells (Figure 4C ), revealing the sufficient reduction
of ATR function.
Collectively, these data demonstrate that G2 arrest driven by R16
and amonafide is ATM-dependent in HCT116 cells.
R16-Induced G2 Arrest Depends on Chk2
As immediate substrates of ATM, the cell cycle checkpoint kinases
Chk1 and Chk2 are responsible for relaying the cell cycle effects of ATM
[12]. To investigate the contribution of Chk1 and Chk2 to R16- and
amonafide-triggered G2 arrest, we depleted Chk1 and Chk2 with their
corresponding specific siRNA, respectively (Figure 5, A and B), and
then examined the cell cycle progression in HCT116 cells. Silencing
Chk1 slightly eased the G2 arrest elicited by R16 and amonafide
(P > .05; Figure 5A). In contrast, depletion of Chk2 reversed R16- and
amonafide-induced G2 arrest with significant statistical difference (P <
.05; Figure 5B). However, knockdown of either Chk1 or Chk2 sta-
tistically significantly diminished the increment of G2-M population in-
duced by the other two classic Top2 inhibitors VP16 and ADR (Figure 5,
A and B). Meanwhile, the cells bearing downregulated Chk2 were more
susceptible to the treatment with R16. As demonstrated in Figure 5C , at
the concentration of 2.5 μM, R16 caused more sub-G1 population
(31.60%) in Chk2-depleted cells than in the mock siRNA-transfected
cells (12.88%). These data suggest a predominant role of Chk2 over
Chk1 in the process of amonafide- and R16-elicited G2 arrest.
Chk2 and Chk1 Are Differentially Phosphorylated by ATM
in Response to the Naphthalimides
To further characterize the differential contribution of Chk1 and
Chk2 to the naphthalimide-elicited G2 arrest, we compared the phos-
phorylation of Chk1 and Chk2. In all the groups treated with different
Top2 inhibitors (R16, amonafide, or VP16) for 24 hours, Chk2 pro-
tein was phosphorylated as indicated by the elevation of p-Chk2 levels,
which was antagonized effectively by the pretreatment with ATM
siRNA1 (Figure 6A). Under the same experimental treatment, how-
ever, phosphorylated Chk1 was undetectable in response to both R16
and amonafide, although Chk1 was normally phosphorylated by the
treatment with VP16, which was also prevented by the pretreatment
with ATM siRNA1 (Figure 6A). In addition, we further confirmed
that the naphthalimides induced the degradation of Chk1 that has
been reported in our previous article [8]. Our data indicate that Chk2
and Chk1 are differentially phosphorylated by ATM in response to
the naphthalimides.
Discussion
Both amonafide and R16 are distinguished from other naphthalimide
analogs for their anticancer activity [4,5,7]. However, the molecular
mechanisms remained to be fully elucidated. We have revealed in de-
tail that both R16 and amonafide target human Top2, thus generating
DNA DSBs in HL-60 cells and leading to G2-M arrest [7]. We have
also demonstrated that R16 induces degradation of Chk1 through the
ubiquitin-proteasome pathway, which contributes to its anticancer ac-
tivity [8]. In the present study, we further specified their cell cycle arrest
precisely at the G2 phase and, more importantly, established the pos-
sible molecular link between DNA DSBs and G2 arrest elicited by R16
and amonafide.
Correctly defining cell cycle arrest by anticancer drugs is important
because it helps clarify the mechanisms of their anticancer activities.
Figure 6. R16 induces differential phosphorylation of Chk2 and Chk1. (A) Chk2 phosphorylation triggered by R16 was blocked by ATM
siRNA1 (100 nM). HCT116 cells were treated with R16, amonafide, or VP16 at the indicated concentrations for 24 hours after being
transfected with 100 nM ATM siRNA1 for 24 hours. Then the cells were subjected to Western blot analysis for Chk1, Chk2, p-Chk1, and
p-Chk2. The images were representative of three independent experiments. (B) Schematic presentation of the possible mechanistic link
between the inhibition of Top2 and G2 arrest elicited by the naphthalimides.
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Moreover, specificity of anticancer drugs in cell cycle arrest has been
taken as a key basis for their combination therapy [25]. Using the
mitosis-specific marker phosphorylated histone H3 and MPM-2 [24],
we demonstrated that few cells were at the M phase in R16- and
amonafide-treated groups HCT116 cells, which corroborated the G2
arrest elicited by these two compounds.
The G2 checkpoint is often activated by DNA DSBs lesions. So
we further confirmed that R16 and amonafide induced DNA DSBs
in HCT116 cells by revealing that both of the compounds enhanced
cellular levels of the phosphorylated histone γ-H2AX and caused the
generation of “comet tails” [26], as they did in HL-60 [7]. After the
generation of DNA DSBs, ATM, the main sensor of DNA DSBs, was
activated by phosphorylation at its serine 1981 in R16- or amonafide-
treated cells. The pan phosphoinositide 3-kinase inhibitor caffeine and
its specific ATM siRNA (including ATM siRNA1 and ATM siRNA2),
but not ATR siRNA, rescued the G2 arrest triggered by R16 and
amonafide, showing a causal link between ATM activation and G2 ar-
rest in the treated cancer cells. Although both the checkpoint kinases
Chk1 and Chk2 are the immediate substrates of ATM [12,14], our
data show that ATM differentially activates them by phosphorylation
and that these two kinases also differentially contribute to the G2 arrest
induced by R16 and amonafide in HCT116 cells. Thus, our data reveal
the mechanism whereby R16 and amonafide induce G2 arrest and
the existence of a mechanistic link between the naphthalimide-caused
DNADSBs signals and the activation of the ATM-Chk2 pathway lead-
ing to the G2 arrest (Figure 6B).
This signaling pathway to G2 arrest used by R16 as well as amonafide
is noticeably different from that used by other classic Top2 inhibi-
tors such as VP16 and ADR. Both VP16 and ADR activate Chk1
and Chk2 similarly by phosphorylation and subsequently lead to G2
arrest [27,28]. In contrast, R16 as well as amonafide differentially
phosphorylates/activates Chk1 and Chk2, consequently, resulting
in G2 arrest in a manner predominantly dependent on Chk2 than
on Chk1. Such differences seem to derive primarily from differential
degradation of Chk1 protein: the naphthalimides induce degradation
of Chk1 through the ubiquitin-proteasome pathway (Figure 6A) [8],
whereas the classic Top2 inhibitors such as VP16 do not (Figure 6A).
Noticeably, these differences are of potential clinical importance. In-
hibitors of Chk1 and Chk2 have been intensively investigated to be
used to potentiate anticancer efficacy of DNA-damaging agents includ-
ing Top2 inhibitors or to circumvent drug resistance to these agents
[29–31]. Our data strongly suggest that both Chk1 and Chk2 inhibi-
tors could be used to sensitize tumor cells to the classic Top2 inhibitors
as reported [31–33]; however, only Chk2 inhibitors could be suitable
for the combination with the naphthalimides owing to Chk1 degrada-
tion resulting from treatments with R16 and amonafide and to ad-
ditional adverse effects possibly deriving from the administration of
Chk1 inhibitors.
Of note, a recently reported naphthalimide analog UNBS5162 has
been shown to be a pan-antagonist of CXCL chemokine expression,
to interfere in vivo with amino acid metabolism, and to trigger pro-
autophagic and senescence-like effects [2,3], which are significantly
different from the mechanisms of action of amonafide and R16. This
is interesting because most of the CXCL chemokines can promote
angiogenesis, and thus, it is understandable that UNBS5162 displays
antiangiogenic properties in vivo in hormone-refractory prostate
cancer models [2,3]. Because UNBS5162 and R16 fall into the same
class in their chemical structures, to further examine whether R16
affects the CXCL chemokines and whether UNBS5162 impacts
the Top2-DNA-cell cycle axis may also be beneficial to fully under-
standing their modes of action.
In summary, our present study demonstrates that the naphthalimides
R16 and amonafide induce DNADSBs, then trigger the ATM-activated
Chk2-executed pathway and finally lead to G2 phase arrest in HCT116
cells while resulting in Chk1 degradation. These features are different
from the classic Top2 inhibitors such as VP16. Apparently, such differ-
ences give new insights into the mechanisms of the cell cycle arrest trig-
gered by Top2 inhibitors on one hand, and sufficiently understanding
these mechanisms forms the crucial basis for the safe, effective combina-
tion of inhibitors of Chk1 or Chk2 with those different Top2 inhibitors
in potential clinical settings on the other.
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